Ascentage Pharma Group International
ASPHFOTCHealthcare● Active
$4.53
$-0.17(-3.51%)
Market Cap$1.7B
P/E Ratio—
52W High$10.65
52W Low$4.53
Ascentage Pharma Group International (ASPHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ASPHF · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 24, 2026EPS Actual
-$0.16
Est. -$0.21 · +23.4%
Revenue
$0.05B
Est. $0.04B · +9.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 24, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
ASPHF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 26, 2026 | -$0.11 | — | — | — | $0.05B | — |
| ◌ Q2 FY2026 | Apr 1, 2026 | -$0.10 | — | — | — | $0.04B | — |
| ▲ Q1 FY2026 | Mar 24, 2026 | -$0.21 | -$0.16 | +23.4% | $0.05B | $0.04B | +9.0% |
| — Q3 FY2025 | Aug 20, 2025 | — | -$0.24 | — | $0.03B | — | — |
| ◌ Q1 FY2025 | Mar 27, 2025 | $0.00 | — | — | — | — | — |
| — Q4 FY2024 | Dec 31, 2024 | — | -$0.26 | — | $0.02B | — | — |
| — Q3 FY2024 | Aug 22, 2024 | — | $0.08 | — | $0.11B | — | — |
| ◌ Q2 FY2024 | May 10, 2024 | — | — | — | — | — | — |
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
-$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 1, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 24, 2026Beat
EPS Actual
-$0.16
EPS Est.
-$0.21
EPS Surpr.
+23.4%
Revenue
$0.05B
Q3 FY2025
Aug 20, 2025
EPS Actual
-$0.24
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q1 FY2025
Mar 27, 2025
EPS Actual
—
EPS Est.
$0.00
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 31, 2024
EPS Actual
-$0.26
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q3 FY2024
Aug 22, 2024
EPS Actual
$0.08
EPS Est.
—
EPS Surpr.
—
Revenue
$0.11B
Q2 FY2024
May 10, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2028 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q2 FY2028 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q1 FY2028 | $-0.92 | $-0.92 | $-0.92 | 1 |
| Q4 FY2027 | $-0.76 | $-0.76 | $-0.76 | 1 |
| Q3 FY2027 | $-1.46 | $-1.46 | $-1.46 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.5B | $0.5B | $0.5B | 1 |
| Q3 FY2028 | $0.5B | $0.5B | $0.5B | 1 |
| Q2 FY2028 | $0.4B | $0.4B | $0.4B | 1 |
| Q1 FY2028 | $0.4B | $0.4B | $0.4B | 1 |
| Q4 FY2027 | $0.4B | $0.4B | $0.4B | 1 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 24, 2026 | +23.4% | $8.48 | $8.48 | +0.00% |
| — Q3 FY2025 | Aug 20, 2025 | — | $10.65 | $10.65 | +0.00% |
| — Q4 FY2024 | Dec 31, 2024 | — | $2.69 | $2.69 | +0.00% |
| — Q3 FY2024 | Aug 22, 2024 | — | $2.69 | $2.69 | +0.00% |
| — Q4 FY2023 | Dec 31, 2023 | — | $3.21 | $3.21 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $4.11 | $4.11 | +0.00% |
| — Q4 FY2022 | Dec 31, 2022 | — | $3.40 | $3.40 | +0.00% |
Q1 FY2026+0.00%
Report Date
Mar 24, 2026
EPS Beat/Miss
+23.4%
Price Before
$8.48
Price After
$8.48
Q3 FY2025+0.00%
Report Date
Aug 20, 2025
EPS Beat/Miss
—
Price Before
$10.65
Price After
$10.65
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
—
Price Before
$2.69
Price After
$2.69
Q3 FY2024+0.00%
Report Date
Aug 22, 2024
EPS Beat/Miss
—
Price Before
$2.69
Price After
$2.69
Q4 FY2023+0.00%
Report Date
Dec 31, 2023
EPS Beat/Miss
—
Price Before
$3.21
Price After
$3.21
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$4.11
Price After
$4.11
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$3.40
Price After
$3.40
Avg Beat Reaction+0.00%
Beat Rate1 / 7 quarters
Largest Move+0.00% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ASPHF ends December
Ascentage Pharma Group International (ASPHF) most recently reported earnings on March 24, 2026 for Q1 FY2026, posting EPS of $-0.16 — beating the analyst consensus of $-0.21 by +23.4%. The next ASPHF earnings date is expected around September 1, 2026.
Each quarter, investors track ASPHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ASPHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ASPHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ASPHF earnings · 5 questionsAscentage Pharma Group International's next earnings report is expected around September 1, 2026. ASPHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ASPHF historically reports after market close (AMC).
ASPHF earnings datewhen is ASPHF earningsASPHF next earnings datewhen does ASPHF report earningsASPHF earnings calendar
▸ Source: FMP · Ascentage Pharma Group International SEC filings · US GAAP · Ascentage Pharma Group International SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026